Fluconazole is indicated in the treatment of mycoses caused by Candida, Cryptococcus and other susceptible yeast, in particular: 1. The treatment of partners who present with symptomatic genital candidiasis should be considered. Prevention of fungal infections in patients predisposed to such infections as a result of chemotherapy or radiotherapy, including bone transplant patients. Dermatomycosis, including infections such as Tinea pedis, Tinea corporis, Tinea cruris, Tinea versicolor. Mucosal candidiasis: These include oropharyngeal candidiasis, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous candidiasis and chronic atrophic oral candidiasis (denture sore mouth). Fluconazole is not indicated for nail infections and tinea capitis. Consideration should be given to official guidance on the appropriate use of antimycotic agents. Both normal hosts and immunocompromised patients may be treated. Before initiating treatment, samples should be taken for microbiological analysis and the suitability of the therapy should be subsequently confirmed (see sections 4.2 and 5.1) In some patients with severe crytococcoal meningitis, the mycological response during fluconazole treatment may be slower that during other treatments (see section 4.4) The daily dose of fluconazole will depend on the nature and severity of the fungal infection. 2 Systemic candidiasis (including disseminated deep infections and peritonitis). Acute cryptococcal meningitis in adults, including patients with AIDS, transplanted patients or other patients with other causes of immunosuppression. Most cases of vaginal candidiasis respond to a single dose treatment. The treatment of those types of infection requiring multiple doses of the drug should be continued until the clinical parameters or laboratory tests indicate that the active fungal infection has subsided. An inadequate treatment period may cause relapses of the active infection. Patients with AIDS and cryptococcal meningitis or recurrent oral candidiasis usually require maintenance treatment to prevent relapses. Currently he is on pulmnicort inhaler 2 puffs Q AM and we have prednisolone to dose PRN if early suspicion of croup is present (i.e. Since he has not shown signs of small airway reactivity is the pulmnicort inhaler of any use? upper gi series and 12 wks of prevacid though he has no signs of GERD. Using this medication, the thrush should clear up in about 1 to 2 weeks. Adults also have pills like fluconazole (Diflucan) and anti fungal throat lozenges called troches. Nystatin is an antifungal agent for mouth thrush and is typically the only medication used when children are diagnosed. They prescribed Nystatin cream- which did not help so they prescribed Diflucan- oral doses for 10 days. And Finally he prescribed Clotrimazole & Betamethasone cream 5 days- which not to my surprise- did NOT help! So his pediatrician prescribed Keflex- oral doses for 10 days - to treat a possible staph infection of his scrotum and anus- no improvement with that. Skin and diaper rashes are treated with Clotrimazole lotions and creams and also clear up in 1 to 2 weeks with treatment. Combos like Minocycline, Diflucan, Rifamphin, Tindamax, Azithromycian, Tetracycline, Plaquenil, Biaxin.
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients aged 10-24 years. A 52-wk open-label, randomized, active-controlled,parallel-group, multicenter study to evaluate efficacy and safety of daprodustat vs recombinant human erythropoietin in subjects w/anemia associated w/chronic kidney disease who are initiating dialysis A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mixed Dyslipidemia A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects with Narcolepsy with Cataplexy A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF) A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications A multicenter open label uncontrolled study of the long term safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 16 years and 11 months of age) with mild to moderate plaque psoriasis A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota TM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis. A P3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multicenter, event driven study in non-dialysis subjects w/anemia associated w/chronic kidney disease to evaluate safety&efficacy of daprodustat compared to darbepoetin alfa A P3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multicenter, event driven study in dialysis subjects w/anemia assoc'd w/chronic kidney disease to evaluate safety&efficacy of daprodustat vs recombinant human erythropoietin A P3, rando'd, dbl-blind, parallel-group, placebo-cont'd study to assess efficacy & safety of 1 or more intradetrusor tx of 600 or 800 units of Dysport for tx of urinary incontinence in subjects w/neurogenic detrusor overactivity d/t spinal injury or MS A Ph 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for Treatment of Intermittent Explosive Disorder (IED) A Ph2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation w/CELLECTRA2000 Alone or in Comb w/Imiquimod for Tx of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of Vulva A Ph3, Open-Label, Randomized Study of Atezolizumab in Combination with Carboplatin or Cisplatin Pemetrexed Compared with Carboplatin or Cisplatin Pemetrexed D in Pts who are Chemotherapy-naive and have Stage IV Non-Squamous Non-Small Cell Lung Cancer A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer A Phase 2 Study of MM-121 in Combination With Docetaxel or Pemetrexed Versus Docetaxel or Pemetrexed Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Safety and Efficacy of Topically-applied AG013 for the Attenuation of Oral Mucositis in Subjects w/Cancers of Head and Neck Receiving Concomitant Chemoradiation Therapy A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled Trial of VTS-270 (2-hydroxypropyl---cyclodextrin) in Subjects with Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease A PHASE 3, PLACEBO CONTROLLED, DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE (i NO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) INOvation-1 A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant A PHASE 3, RANDOMIZED, MULTICENTER, SINGLE-BLIND CONTROLLED STUDY EVALUATING ARTERIOVENOUS FISTULA OUTCOMES WITH AND WITHOUT A PERIVASCULAR SIROLIMUS-ELUTING COLLAGEN IMPLANT IN SUBJECTS ON HEMODIALYSIS (THE ACCESS TRIAL) A Phase 3, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus-Eluting Collagen Implant in Subjects on Hemodialysis A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2879552 given orally in subjects withrelapsed/refractory acute myeloid leukemia A Phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER breast cancer A Phase I/IIa, Open-label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy A Phase II Multi-Center, Randomized, Double-Blind, 24-Week, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 with Autism Spectrum Disorder (ASD) A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150] A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN- (r Ad-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC). A Phase WW Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody Ch14.18 (Dinutuximab, NSC764038, IND 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma. A prospective, open label Phase I/II study to assess the safety and efficacy of cycles of intravenously infused doses of OPN-305 in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVENOUS CEFTOLOZANE/TAZOBACTAM COMPARED WITH MEROPENEM IN ADULT PATIENTS WITH VENTILATED NOSOCOMIAL PNEUMONIA A Rando'd, Double-Blind, Placebo-Cont'd Trial to Evaluate Safety, Tolerability, PK and Efficacy of Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Diff Toxin B) in Children 1 to A randomized Phase II trial of Fulvestrant with or without Ribociclib (LEE011) after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with advanced hormone receptor positive, HER2 negative breast cancer A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407) A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Pragmatic Clinical Trial To Evaluate The Effectiveness Of Low Dose Oral Methotrexate In Patients With Pediatric Crohn's Disease Initiating Anti-TNF Therapy (COMBINE) A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of Avelumab (MSB0010718C) in combination with and/or following chemotherapy in patients with previously untreated epithelial ovarian cancer A randomized, open-label, multicenter, two arm, phase IIstudy to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients with iron overload A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib NSC 761968, Crizotinib NSC 749005, Savolitinib NSC 785348, and Sunitinib NSC 736511) in Metastatic Papillary Renal Carcinoma (PAPMET) A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY) An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies An open label phase II study to evaluate the efficacy andsafety of PDR001 in patients with advanced or metastaticnon-functional neuroendocrine tumors of pancreatic,gastrointestinal (GI), or thoracic origin who haveprogressed on prior treatment Clinical Study of the Reversal of Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study Global Congestive Heart Failure (G-CHF) Study: A Global Registry to Study the Demographics, Socioeconomic and Clinical Factors, Etiologies, Pathophysiology, Management, Barriers to Care, and Outcomes of Heart Failure Patients IRON CLAD Can Iron Lessen Anemia Due to cancer and chemotherapy A multi-center, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer- (ferric carboxymaltose injection). LONG-TERM FOLLOW-UP FOR PARTICIPANTS OF EVALUATION OF OUTCOMES FOLLOWING MITRAL VALVE REPAIR/REPLACEMENT IN SEVERE CHRONIC ISCHEMIC MITRAL REGURGITATION (SMR) AND SURGICAL INTERVENTIONS FOR MODERATE ISCHEMIC MITRAL REGURGITATION (MMR) TRIALS Multicenter Cohort Study To Evaluate Outcomes After Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (i Cat) Recommendations in Children and Young Adults With Solid Tumors: The i Cat2, GAIN Consortium Study Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Viremia or Malignancies for Whom there are No Appropriate Alternative Therapies Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia Open-label, non-rando'd, multicntr Ph I study to determine max tolerated and/or recomm'd Ph II dose of oral mutant IDH1 (m IDH1) inhibitor BAY1436032 and characterize safety, tolerability, PK, PD, and prelim clin efficacy in pts w/m IDH1-R132X advanced AML PALbociclib Co Llaborative Adjuvant Study: Rando'd P3 Trial of Palbociclib w/Std Adjuvant Endocrine Therapy vs Std Adjuvant Endocrine Thrpy Alone for Hormone Receptor Postve (HR )/Human Epidermal Growth Factor Receptor 2 Negtve (HER2-) Early Breast Cancer Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. ABSTRACT QUESTION I have a patient with persistent breast and nipple thrush. Other therapies have failed, so I have decided to treat her with a loading dose of 400 mg of oral fluconazole followed by 100 mg twice daily for at least 2 weeks. Is there any need for her to interrupt breastfeeding during this treatment? ANSWER Available data regarding fluconazole use during breastfeeding are reassuring. Fluconazole is also used in the treatment of fungal diseases in infants and has a good safety profile. Therefore, there is no need to interrupt breastfeeding when a mother is treated with fluconazole. QUESTION Une de mes patientes souffre d'une candidose aux seins et aux mamelons.
QT prolongation Torsades de pointes Alopecia Anaphylactic reactions Angioedema Cholestasis Dizziness Dyspnea Hepatic failure Hepatitis Hypertriglyceridemia Hypokalemia Increased alkaline phosphatase Increased ALT/AST Jaundice Leukopenia Pallor Seizures Stevens-Johnson syndrome Taste perversion Thrombocytopenia Toxic epidermal necrolysis Hypersensitivity to other azoles Use caution in proarrhythmic conditions and renal impairment Use extreme caution or avoid in congenital long-QT patients and patients with conditions that increase QT-prolongation risk Fluconazole inhibits CYP2C9, CYP2C19, and CYP3A4 isoenzymes; coadministration with drugs that are substrates if these isoenzymes may be contraindicated or warrant dosage modifications Capsules contain lactose and should not be given to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption Powder for oral suspension contains sucrose and should not be used in patients with hereditary fructose, glucose/galactose malabsorption or sucrase-isomaltase deficiency Syrup contains glycerol; may cause headache, stomach upset, and diarrhea Hepatotoxicity reported with use; use with caution in patients with hepatic impairment Rare exfoliative skin disorders reported; monitor closely if rash develops and discontinue if it progresses When driving vehicles or operating machines, it should be taken into account that dizziness or seizures may occasionally occur Candida krusei is inherently resistant Convenience and efficacy of single dose oral tablet of fluconazole regimen for the treatment of vaginal yeast infections should be weighed against acceptability of higher incidence of drug related adverse events with fluconazole (26%) versus intravaginal agents (16%) If drug is used during pregnancy or if patient becomes pregnant while taking the drug, patient should be informed of potential hazard to fetus; effective contraceptive measures should be considered in women of child-bearing potential who are being treated with 400 to 800 mg/day and should continue throughout the treatment period and for approximately 1 week (5 to 6 half-lives) after the final dose Highly selective inhibitor of fungal cytochrome P-450-dependent enzyme lanosterol 14-alpha-demethylase Subsequent loss of normal sterols correlates with accumulation of 14 alpha-methyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole Additive: TMP-SMX Y-site: Amphotericin B, amphotericin B cholesteryl sulfate, ampicillin, calcium gluconate, cefotaxime, ceftazidime(? ), ceftriaxone, cefuroxime, chloramphenicol, clindamycin, co-trimoxazole, diazepam, digoxin, erythromycin lactobionate, furosemide, haloperidol, hydroxyzine, imipenem/cilastatin, pentamidine, piperacillin, ticarcillin, TMP-SMX Solution: D5W, LR Additive: Acyclovir, amikacin, amphotericin B, cefazolin, ceftazidime, ciprofloxacin, clindamycin, gentamicin, heparin, meropenem, metronidazole, morphine, piperacillin, potassium chloride, ranitidine with ondansetron, theophylline Y-site: Acyclovir, aldesleukin, allopurinol, amifostine, amikacin, aminophylline, amiodarone, ampicillin-sulbactam, aztreonam, benztropine, bivalirudin, cefazolin, cefepime, cefotetan, cefoxitin, cefpirome, chlorpromazine, cimetidine, cisatracurium, dexamethasone sodium phosphate, dexmedetomidine, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doxorubicin liposomal, droperidol, etoposide PO4, famotidine, fenoldopam, filgrastim, fludarabine, foscarnet, ganciclovir, gatifloxacin, gemcitabine, gentamicin, granisetron, heparin, hetastarch, hydrocortisone, immune globulin, leucovorin, linezolid, lorazepam, melphalan, meperidine, meropenem, metoclopramide, metronidazole, midazolam, morphine, nafcillin, nitroglycerin, ondansetron, oxacillin, paclitaxel, pancuronium, penicillin G, phenytoin, piperacillin-tazobactam, prochlorperazine, promethazine, propofol, quinupristin-dalfopristin, ranitidine, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin-clavulanate, tobramycin, vancomycin, vecuronium, vinorelbine, zidovudine Tablets: Store below 86° F (30° C) Dry powder: Store below 86° F (30° C); reconstituted suspension should be stored between 86° F (30° C) and 41° F (5° C), and unused portion should be discarded after 2 weeks; protect from freezing Injection (glass bottles): Store between 86° F (30° C) and 41° F (5° C); protect from freezing Injection (Viaflex Plus plastic containers): Store between 77° F (25° C) and 41° F (5° C); protect from freezing The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. 150 mg orally as a single dose Infectious Diseases Society of America (IDSA) Recommendations: -Uncomplicated vaginitis: 150 mg orally as a single dose -Management of recurrent vulvovaginal candidiasis (after 10 to 14 days induction therapy): 150 mg orally once a week for 6 months -Complicated vulvovaginal candidiasis: 150 mg orally every 72 hours for 3 doses US CDC Recommendations: -Uncomplicated vulvovaginal candidiasis: 150 mg orally as a single dose -Initial therapy for recurrent vulvovaginal candidiasis: 100 to 200 mg orally every 72 hours for 3 doses -Maintenance therapy for recurrent vulvovaginal candidiasis: 100 to 200 mg orally once a week for 6 months -Severe vulvovaginal candidiasis: 150 mg orally every 72 hours for 2 doses US CDC, National Institutes of Health (NIH), and IDSA Recommendations for HIV-infected Patients: -Uncomplicated vulvovaginal candidiasis: 150 mg orally as a single dose -Severe or recurrent vulvovaginal candidiasis: 100 to 200 mg orally once a day for at least 7 days -Suppressive therapy for vulvovaginal candidiasis: 150 mg orally once a week Comments: -Recommended as preferred therapy -Unless frequent or severe recurrences, suppressive therapy generally not recommended Oropharyngeal candidiasis: 200 mg IV or orally on the first day followed by 100 mg IV or orally once a day Duration of therapy: At least 2 weeks, to reduce the risk of relapse IDSA Recommendations: -Moderate to severe oropharyngeal candidiasis: 100 to 200 mg IV or orally once a day for 7 to 14 days Comments: -Recommended as primary therapy US CDC, NIH, and IDSA Recommendations for HIV-infected Patients: -Initial episodes of oropharyngeal candidiasis: 100 mg orally once a day for 7 to 14 days -Suppressive therapy for oropharyngeal candidiasis: 100 mg orally once a day or 3 times a week Comments: -Recommended as preferred oral therapy -Unless frequent or severe recurrences, suppressive therapy generally not recommended Doses up to 400 mg/day have been used. Comments: -Optimal therapeutic dose and therapy duration have not been established. Use: For systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia IDSA Recommendations: Candidemia in nonneutropenic or neutropenic patients: 800 mg IV or orally on the first day followed by 400 mg IV or orally once a day Duration of therapy: -Nonneutropenic patients: 14 days after first negative blood culture and candidemia signs/symptoms resolve -Neutropenic patients: 2 weeks after Candida cleared from bloodstream (documented) and candidemia symptoms and neutropenia resolve Chronic disseminated candidiasis in stable patients: 400 mg IV or orally once a day Duration of therapy: Until lesions have resolved (usually months) and through periods of immunosuppression Candida osteoarticular infection: 400 mg IV or orally once a day Duration of therapy: -Osteomyelitis: 6 to 12 months -Septic arthritis: At least 6 weeks CNS candidiasis (after initial regimen of IV amphotericin B): 400 to 800 mg IV or orally once a day Duration of therapy: Until all signs/symptoms and CSF and radiologic abnormalities resolve Candida cardiovascular system infection: 400 to 800 mg IV or orally once a day Duration of therapy: -Endocarditis: Lifelong suppressive therapy may be indicated. -Pericarditis or myocarditis: Often several months -Suppurative thrombophlebitis: At least 2 weeks after candidemia cleared -Infected pacemaker, implantable cardioverter defibrillator (ICD), or ventricular assist device (VAD): 4 to 6 weeks after device removed; chronic suppressive therapy if VAD not removed Comments: -Candidemia in nonneutropenic patients: Recommended as primary therapy; an echinocandin is recommended for moderately severe to severe illness or recent azole exposure; switching to this drug after initial echinocandin is often appropriate. -Candidemia in neutropenic patients: Recommended as alternative therapy; an echinocandin or IV amphotericin B preferred for most patients; this drug recommended for patients without recent azole exposure and who are not critically ill. -Recommended as primary therapy for chronic disseminated candidiasis in stable patients, Candida osteoarticular infection, CNS candidiasis, pericarditis/myocarditis, and suppurative thrombophlebitis -Recommended as alternative therapy for endocarditis and infected pacemaker, ICD, or VAD Doses up to 400 mg/day have been used. Comments: -Optimal therapeutic dose and therapy duration have not been established.
Fluconazole is a white crystalline solid which is slightly soluble in water and saline. DIFLUCAN Tablets contain 50, 100, 150, or 200 mg of fluconazole and the following inactive ingredients microcrystalline cellulose, dibasic calcium phosphate anhydrous, povidone, croscarmellose sodium, FD&C Red No. 40 aluminum lake dye, and magnesium stearate. Fluconazole is used to treat common fungal infections- Difulcan is one such Fluconazole for fungalIt is usually taken as a single 150 mg dose for vaginal thrush. You can take it at any time of day.